Core Viewpoint - BofA Securities upgraded Regeneron Pharmaceuticals from Underperform to Buy and raised its price target to $860.00 from $627.00, leading to a more than 2% increase in stock price during pre-market trading [1] Group 1: Eylea and Dupixent Outlook - BofA's previous bearish stance on Eylea SD has largely played out, with consensus expectations declining [2] - The firm is more optimistic about Eylea HD following multiple label updates, with estimates now significantly above consensus [2] - Additional growth potential is anticipated from Dupixent, which is marketed in partnership with Sanofi [2] Group 2: Pipeline and Future Catalysts - The analyst pointed out pipeline optionality for 2026, including a Phase 3 melanoma readout for fianlimab, a LAG-3 antibody, expected in the first half of the year [3] - Potential positive updates at a competitor conference in January are seen as another catalyst for Regeneron [3] - BofA expects a favorable outcome from Regeneron's MFN agreement with the White House, which may alleviate any remaining MFN-related concerns, including a likely exemption from MFN CMMI demonstration projects [3]

SAN JOSE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrightInsight, Inc. (“BrightInsight”), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, highlighting the positive impact of the Patient App on adherence and persistence for one of Sanofi and Regeneron’s key biologic therapies. Adherence remains a major challenge for the pharmaceutical industry—particularly with self-injected therapies administered at home. Despite substantial investm ...

David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an indep ...

Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter syndromeExpecting multiple clinical data readouts from pipeline programs including for Sanfilippo syndrome Type A (ETV:SGSH), granulin-related frontotemporal dementia (PTV:PGRN) and Parkinson’s disease (LRRK2 inhibitor)Planning for initiation of first-in-human clinical studies with TV-enabled therapeutics for Alzheimer’s disease (OTV:MAPT, ATV:Abeta) and Pompe dis ...

CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced today that Sanofi is making a $30 million investment to accelerate Enable’s manufacturing build-out, strengthen its supply chain capabilities, and drive commercial growth. “This investment from one of our key partners shows support of the enFuse platform and our shared commitment to making large-volume subcutaneous ...

人民财讯1月6日电，赛诺菲1月6日宣布，创新药物瑞达普（普乐司兰钠注射液）正式获得国家药品监督 管理局（NMPA）批准，在饮食控制基础上，用于降低家族性乳糜微粒血症综合征（FCS）成人患者的 甘油三酯水平。FCS是一种高甘油三酯水平相关的遗传性疾病。作为全球首个作用于创新靶点APOC3 （载脂蛋白C-III）mRNA的小干扰RNA（siRNA）药物，普乐司兰钠注射液能够将FCS患者空腹甘油三 酯水平较基线降低80%、急性胰腺炎发生率较安慰剂降低80%，且仅需一年四次给药，破解了FCS现阶 段在中国"无药可控"的困局。 ...

Click here for more info https://monteverdelaw.com/case/dynavax-technologies-corporation/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with ...

Key Takeaways Sanofi seeks FDA approval to expand Tzield use to children aged one and older with stage 2 T1D.SNY's filing received priority review, with an FDA decision expected by April 29, 2026.The application is backed by interim phase IV PETITE-T1D data in children under eight.Sanofi (SNY) announced that the FDA has accepted a regulatory filing seeking to expand the use of its type 1 diabetes (T1D) drug, Tzield (teplizumab), in individuals aged one year and older. The agency has granted priority review ...

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. “We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with ...

Core Viewpoint - The company announced that the regulator has accepted a priority review to potentially expand the age range for its Tzield type-1 diabetes drug to include children as young as one year old [1] Group 1 - The priority review indicates a significant step towards making the Tzield drug available for younger patients [1]